[1]
|
Stroke Risk in Atrial Fibrillation Working Group (2008) Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke, 39, 1901-1910.
doi:10.1161/STROKEAHA.107.501825
|
[2]
|
Lip, G.Y., Nieuwlaat, R., Pisters, R. , Lane, D.A. and Crijns, H.J. (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest, 137, 263-272.
doi:10.1378/chest.09-1584
|
[3]
|
Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. Journal of the American Medical Association, 285, 2864-2870.
doi:10.1001/jama.285.22.2864
|
[4]
|
Bristol-Myers Squibb (2010) Coumadin Prescribing Information.
|
[5]
|
Aspinall, S.L., DeSanzo, B.E., Trilli, L.E. and Good, C.B. (2005) Bleeding risk index in an anticoagulation clinic. Assessment by indication and implications for care. Journal of General Internal Medicine, 20, 1008-1013.
doi:10.1111/j.1525-1497.2005.0229.x
|
[6]
|
Gage, B.F., Yan, Y., Milligan, P.E., et al. (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 151, 713-719.
doi:10.1016/j.ahj.2005.04.017
|
[7]
|
Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Journal of the American Medical Association, 285, 2370-2375. doi:10.1001/jama.285.18.2370
|
[8]
|
Lin, P. (2005) Reviewing the reality: Why we need to change. European Heart Journal, 7, E15-E20.
|
[9]
|
Walker, A.M. and Bennett, D. (2008) Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm, 5, 1365-1372.
doi:10.1016/j.hrthm.2008.07.014
|
[10]
|
Singer, D.E., Albers, G.W., Dalen, J.E., et al. (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 133, 546S-592S.
doi:10.1378/chest.08-0678
|
[11]
|
Lakshminarayan, K., Solid, C.A., Collins, A.J., Anderson, D.C. and Herzog, C.A. (2006) Atrial fibrillation and stroke in the general Medicare population: A 10-year perspective (1992 to 2002). Stroke, 37, 1969-1974.
doi:10.1161/01.STR.0000230607.07928.17
|
[12]
|
Waldo, A.L., Becker, R.C., Tapson, V.F., Colgan, K.J. (2005) Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. Journal of the American College of Cardiology, 46, 1729-1736.
doi:10.1016/j.jacc.2005.06.077
|
[13]
|
Deplanque, D., Leys, D., Parnetti, L., et al. (2004) Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. British Journal of Clinical Pharmacology, 57, 798-806. doi:10.1111/j.1365-2125.2004.02086.x
|
[14]
|
Lip, G.Y. and Tse, HF. (2007) Management of atrial fibrillation. Lancet, 370, 604-618.
doi:10.1016/S0140-6736(07)61300-2
|
[15]
|
Centers for Disease Control and Prevention (2011) Classification of Diseases, Functioning, and Disability.
http://www.cdc.gov/nchs/icd.htm
|
[16]
|
American Medical Association (2009) CPT 2010 Standard Edition (Current Procedural Terminology (CPT) Standard). American Medical Association Press, Chicago.
|
[17]
|
Hart, R.G., Pearce, L.A. and Aguilar, M.I. (2007) Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine, 146, 857-867.
|
[18]
|
Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V. and Singer, D.E. (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Annals of Internal Medicine, 131, 927-934.
|
[19]
|
Fleiss, J., Levin, B. and Paik, M. (2003) Statistical methods for rates and proportions. 3rd Edition, John Wiley & Sons Inc., Hoboken. doi:10.1002/0471445428
|
[20]
|
Koch, G., Atkinson, S. and Stokes, M. (1986) Poisson regression. In: Johnson, N.L. and Kotz, S., Eds. Encyclopedia of Statistical Sciences. John Wiley & Sons, Inc., Hoboken, 32-41.
|
[21]
|
Stokes, M., Davis, C., Koch, G. (2009) Categorical data analysis using the SAS system. 2nd Edition, SAS Institute, Carey.
|
[22]
|
Kowey, P.R., Reiffel, J.A., Myerburg, R., et al. (2010) Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). American Journal of Cardiology, 105, 1130-1134.
doi:10.1016/j.amjcard.2009.11.047
|
[23]
|
Nieuwlaat, R., Capucci, A., Lip, G.Y., et al. (2006) Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. European Heart Journal, 24, 3018-3026.
doi:10.1093/eurheartj/ehl015
|
[24]
|
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. and Palareti, G. (2008) Pharmacology and manage- ment of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Gui- delines (8th edition). Chest, 133, 160S-198S.
doi:10.1378/chest.08-0670
|
[25]
|
Weitz, J.I., Hirsh, J. and Samama, M.M. (2008) New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 133, 234S-256S.
doi:10.1378/chest.08-0673
|
[26]
|
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139- 1151. doi:10.1056/NEJMoa0905561
|
[27]
|
Patel M.R. (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. American Heart Journal, 159, 340-347.
doi:10.1016/j.ahj.2009.11.025
|
[28]
|
Kolominsky-Rabas, P.L., Weber, M., Gefeller, O., Neundoerfer, B. and Heuschmann, P.U. (2001) Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke, 32, 2735-2740. doi:10.1161/hs1201.100209
|
[29]
|
Petty, G.W., Brown, R.D., Jr., Whisnant, J.P., Sicks, J.D., O’Fallon, W.M. and Wiebers, D.O. (2000) Ischemic stroke subtypes: A population-based study of functional outcome, survival, and recurrence. Stroke, 31, 1062-1068.
doi:10.1161/01.STR.31.5.1062
|